Abstract
Utilization of vaccines generated by fusion of dendritic cells and tumour cells is a promising approach to tumour immunotherapy. We have examined the therapeutic efficacy of vaccines generated by fusion of HPV16-associated tumour cells TC-1 with syngeneic and allogeneic dendritic cells. Locally administered hybrid cells generated by fusion of MHC class I+ TC-1 cells and syngeneic DC inhibited the growth of MHC class I+ TC-1 tumours, but not the growth of MHC class I- TC-1/A9-derived tumours. The growth of TC-1 tumours was also inhibited by hybrids generated by fusion of TC-1 cells and allogeneic DC. The therapeutic efficacy was enhanced by co-administration of the vaccine with synthetic immunostimulatory ODN CpG 1826.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / pharmacology
-
Animals
-
Cancer Vaccines / immunology
-
Cancer Vaccines / pharmacology*
-
Cell Line, Tumor / immunology*
-
Cell Line, Tumor / transplantation
-
Cell Proliferation / drug effects
-
Dendritic Cells / cytology
-
Dendritic Cells / immunology*
-
Histocompatibility Antigens Class I / immunology
-
Histocompatibility Antigens Class I / metabolism
-
Hybrid Cells / immunology*
-
Hybrid Cells / transplantation*
-
Immunotherapy / methods*
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Mice, Inbred C57BL
-
Neoplasm Transplantation
-
Oncogene Proteins, Viral / genetics
-
Repressor Proteins / genetics
-
Treatment Outcome
Substances
-
Adjuvants, Immunologic
-
Cancer Vaccines
-
E6 protein, Human papillomavirus type 16
-
Histocompatibility Antigens Class I
-
Oncogene Proteins, Viral
-
Repressor Proteins